Praxis Precision Medicines
Biotechnology
Praxis Precision Medicines is a clinical-stage, central nervous system (CNS) precision neuroscience biopharmaceutical company that translates insights from genetic epilepsies into therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. It is publicly traded on Nasdaq under ticker PRAX and is transitioning toward commercialization of its first therapies.
- Cerebrum™ small molecule platform (ulixacaltamide, vormatrigine, relutrigine, PRAX-020, PRAX-050)
- Solidus™ antisense oligonucleotide platform (elsunersen, PRAX-080, PRAX-090, PRAX-100)
Open roles at Praxis Precision Medicines
1 matching role
Remote · Director
Remote eligibility: United States
$220k to $240k USD
- Management Occupations
- Toxicology
Posted 4 weeks ago
Source: Greenhouse
Showing 1 of 1 roles